Athenex to participate in truist securities cell therapy symposium

Buffalo, n.y., june 23, 2022 (globe newswire) -- athenex (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that daniel lang, m.d., president, athenex cell therapy, will participate in the next cells & mechanisms to watch in oncology panel at the truist securities cell therapy symposium on tuesday, june 28, 2022 at 11:30 am eastern time in new york, ny. company management will also participate in one-on-one investor meetings during the event.
ATNX Ratings Summary
ATNX Quant Ranking